| |
|
|
|
Catabasis Pharmaceuticals Inc.  
|
|
7 0.06 (0.01%) |
09-18 16:00 |
|
Open: |
7 |
Pre close: |
6.94 |
Target:
|
8.68
|
|
High: |
7.09 |
Low: |
6.83 |
Resistance:
|
7.43
8.59
|
|
Volume: |
311,297 |
Market Cap: |
134M |
Support:
|
5.55
4.62
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
6.83
 |
MACD |
MACD(12,26):
|
0.02 |
|
MA(20): |
6.80 |
Signal(12,26,9): |
-0.02 |
|
MA(100): |
6.54 |
Stochastic Oscillator |
%K(14,3):
|
76.68 |
|
MA(250): |
5.72 |
%D(3): |
59.71 |
|
Average Volume(K) |
3-Month: |
33349
|
52-Week |
High:
|
8.59 |
|
10-Days: |
27438 |
Low: |
2.74 |
|
RSI |
RSI(14):
|
54.48 |
Change(%): |
23.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.130 |
Return on Equity (ttm) |
-64.9 |
Shares Out. (M) |
19.08 |
|
EPS Est. Current Year |
-1.390 |
Return on Assets (ttm) |
-36.7 |
Shares Float (M) |
19.05 |
|
EPS Est. Next Year |
-1.100 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.57 |
|
EPS Est. Next Quarter |
-0.330 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
40.87 |
|
Forward EPS |
-2.350 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
767 |
|
Book Value (p.s.) |
2.700 |
EBITDA (p.s.) |
-1.625 |
P/E |
-3.29 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.59 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-28.70 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-17.90 |
P/CF |
-4.65 |
|
|
|
|
|
|
